Lifecore Biomedical, Inc.

Good afternoon, and thank you for joining LifeCore's financial 2025 second quarter earnings call. During the call, all participants will be in a listen-only mode. Now, I would like to turn the call over to Stephanie Diaz, Manager of Investor Relations for LifeCore. Please go ahead.

Good afternoon, and thank you for joining us today to discuss LifeCore Biomedical's second quarter fiscal 2025 earnings results. Hosting the call today from LifeCorps are Paul Josephs, President and Chief Executive Officer, and Ryan Lake, Chief Financial Officer. Before we begin today, we'd like to remind everyone that certain statements made in the course of this conference call contain forward-looking statements. It is important to note that the forward-looking statements made during this call reflect management's judgment and analysis only as of today, January 2nd, 2025. and the company's actual results could differ materially from those projected in such forward-looking statements. For a more thorough discussion of the risks and uncertainties associated with any forward-looking statements, please see the disclaimer regarding forward-looking statements that is included in our fiscal 2025 second quarter earnings release, which was furnished to the SEC today on Form 8K, as well as our other filings with the Securities and Exchange Commission, including but not limited to the company's Form 10Q for Q2 fiscal 2025, which was filed this afternoon. With that, I'd like to turn the call over to Paul Joseph, Chief Executive Officer.

Thank you, Stephanie. Good afternoon, everyone, and thank you for joining our fiscal 2025 second quarter update. The second quarter was a very productive time at LifeCorps. Our achievements during this period span finance, operations, and business development. all of which supported our overall growth strategy. Revenues in the period were strong and in line with our fiscal guidance. Gross margins were improved during the period as compared to Q1 margins, reflecting greater leverage over our overhead costs across increased revenues and a favorable sales mix. Our business development team was successful in finding multiple new projects. And importantly, our balance sheet was materially strengthened during the period with the combination of the successful completion of our previously announced pipe financing and the restructuring of our revolving credit facility with BMO on significantly improved terms for LifeCorps. I will provide additional details on business development and operations for the period following an overview of our second quarter fiscal 2025 financial results. For that, I'll turn the call over to Ryan.